Akademik Veri Yönetim Sistemi
V. International Agricultural, Biological & Life Science Conference (Agribiol 2023), Edirne, Türkiye, 18 - 20 Eylül 2023, ss.562
Piroxicam is used to treat pain or inflammation in the body caused by rheumatoid arthritis and
osteoarthritis. It is in a class of medications called nonsteroidal anti-inflammatory drugs. This
study aims to evaluate the possible DNA damaging effect of Piroxicam on human peripheral
lymphocytes using comet (Single Cell Gel Electrophoresis-SCGE) assay. Comet assay is a
popular, sensitive, quick, and low-cost technique for detecting DNA strand breakage. This assay
has become a standard test used to evaluate the safety of novel pharmaceuticals or chemicals.
In this study, peripheral blood from two healthy donors (one male and one female) was
suspended in PBS and then lymphocytes were isolated. Isolated lymphocytes were treated with
various concentrations of Piroxicam (0.23, 0.47, 0.94, 1.88, and 3.75 μg/mL) at 37°C for 1 h.
A negative and a positive (100 μM H2O2) and solvent controls (4,81 μl/mL) were also used for
each treatment. Comets were scored using the tail length (µm), tail intensity (%), and tail
moment of 100 comets on each slide (a total of 200 comets for each concentration). This study
was approved by the ethical committee of Amasya University (2021/86). As a result, Piroxicam
decreased the comet tail length at 0.23 and 0.94 μg/mL and tail moment at 0.23 μg/mL
compared to solvent control. This anti-inflammatory drug slightly reduced the comet tail length
in isolated human lymphocytes. Therefore, it did not cause DNA damage. However, these
results should be supported by other genotoxicity assays.